Human T Lymphoblast Stably Deoxycytidine Kinase Deficient (AraC-8C) Cell Line

Human T lymphoblasts are susceptible to HIV infection, and past studies had focused on the anti-HIV drug, 2‘,3‘-dideoxycytidine (ddC) for treatment. ddC relies on the nucleoside transport system and studies have linked the deoxycytidine kinase is involved in drug metabolism. The Human T Lymphoblast Stably Deoxycytidine Kinase Deficient Cell Line (AraC-8C) is a mutant clonal derivative of the CCRF-CEM cell line, which is also hypoxanthine-guanine phosphoribosyltransferase-deficient. AraC-8D cells are able to grow in the presence of 5 µM arabinosylcytosine and are deficient in nucleoside transport activities making it resistant to ddC unlike the parental cells. Additionally, the cells exhibit resistance to Ara-C, commonly used anti-cancer chemotherapy drug. It is valuable for research relating to the functions of nucleoside transport and related pathways, and for anti-cancer chemotherapeutic analysis.